Company / SG&A Expense
RIGEL PHARMACEUTICALS INC SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$115.9M
FY2025
5-year range
$91.9M / $115.9M
FY2021-FY2025
Trend
+2.5%
vs FY2024
Sector context
#105 of 213
Health Care
What the data says
At $116M, RIGEL PHARMACEUTICALS INC's sg&a expense ranks #109 of 213 in the Health Care sector. SG&A Expense has fluctuated over the past 10 years, ranging from $21M in FY2018 to $116M in FY2025.
Based on SEC 10-K filings.
$116M in FY2025 with a 5-year CAGR of +8.6%.
Increased from $106M to $116M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +1.0%
- 5-Year CAGR
- +8.6%
- 10-Year CAGR
- -
Sector benchmark
#109 of 213 in Health CareTop 51% of 213This company $115.9M Sector average $722.3M
▼
-84.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +8.6%, indicating consistent growth.
- In FY2025, sg&a expense increased 2.5% year-over-year.
- Ranks #105 out of 213 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $115.9M | +2.5% |
| FY2024 | $113.1M | +6.9% |
| FY2023 | $105.7M | -6.0% |
| FY2022 | $112.5M | +22.4% |
| FY2021 | $91.9M | +20.0% |
| FY2020 | $76.6M | +2.7% |
| FY2019 | $74.6M | +256.7% |
| FY2018 | $20.9M | -44.7% |
| FY2017 | $37.8M | +80.9% |
| FY2016 | $20.9M | +17.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026